Maravai Lifesciences Company Top Insiders

MRVI Stock  USD 2.30  0.06  2.68%   
Under 67% of Maravai Lifesciences' corporate insiders are selling. The analysis of insiders' sentiment of trading Maravai Lifesciences Holdings stock suggests that many insiders are alarmed at this time. Maravai Lifesciences employs about 570 people. The company is managed by 17 executives with a total tenure of roughly 1330 years, averaging almost 78.0 years of service per executive, having 33.53 employees per reported executive.

Insider Sentiment 33

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-01-31Kurt OreshackDisposed 25000 @ 5.03View
2024-11-11Carl HullAcquired 175000 @ 5.64View
2024-05-28Gtcr Investment Xi LlcDisposed 9940974 @ 9.81View
Monitoring Maravai Lifesciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Maravai Lifesciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.0364) % which means that it has lost $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3798) %, meaning that it created substantial loss on money invested by shareholders. Maravai Lifesciences' management efficiency ratios could be used to measure how well Maravai Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The Maravai Lifesciences' current Return On Tangible Assets is estimated to increase to -0.21. The Maravai Lifesciences' current Return On Capital Employed is estimated to increase to -0.24. As of now, Maravai Lifesciences' Non Currrent Assets Other are increasing as compared to previous years. The Maravai Lifesciences' current Other Assets is estimated to increase to about 973.4 M, while Other Current Assets are projected to decrease to under 15.4 M.
The Maravai Lifesciences' current Common Stock Shares Outstanding is estimated to increase to about 167.4 M. The Maravai Lifesciences' current Net Income Applicable To Common Shares is estimated to increase to about 265.9 M

Maravai Lifesciences Workforce Comparison

Maravai Lifesciences Holdings is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 16,990. Maravai Lifesciences holds roughly 570 in number of employees claiming about 3% of equities under Health Care industry.

Maravai Lifesciences Profit Margins

The company has Profit Margin (PM) of (0.56) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.48) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.48.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.670.4179
Way Up
Slightly volatile

Maravai Lifesciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Maravai Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Maravai Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Maravai Lifesciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
0.375
6
16
 2,613,415 
 459,115 
2024-12-01
2.6667
8
3
 353,515 
 75,851 
2024-06-01
4.0
16
4
 8,625,295 
 26,777,624 
2024-03-01
0.8
8
10
 2,275,247 
 64,854 
2023-12-01
1.5
3
2
 4,039 
 70,746 
2023-09-01
11.0
11
1
 547,901 
 5,578 
2023-03-01
1.1111
10
9
 1,129,422 
 4,754,486 
2022-03-01
3.3333
10
3
 434,000 
 13,300 
2021-12-01
7.0
14
2
 44,445 
 5,140,830 
2021-06-01
0.6667
4
6
 2,194 
 38,365,959 
2020-12-01
7.0
21
3
 645,500 
 64,823,011 

Maravai Lifesciences Notable Stakeholders

A Maravai Lifesciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Maravai Lifesciences often face trade-offs trying to please all of them. Maravai Lifesciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Maravai Lifesciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Carl HullCoFounder ChairmanProfile
Robert MBAChairman BoardProfile
Andrew BurchPresident ProductionProfile
Kevin HerdeExecutive CFOProfile
Kevin CPAExecutive CFOProfile
Kurt OreshackGeneral VPProfile
Kurt JDGeneral VPProfile
Christine DolanExecutive TechnologiesProfile
Brian NeelChief ProductionProfile
Peter LeddyExecutive OfficerProfile
Christopher BenoitExecutive EnzymesProfile
Becky BuzzeoExecutive OfficerProfile
Kate BroderickExecutive OfficerProfile
Rebecca BuzzeoExecutive OfficerProfile
Debra HartDirector RelationsProfile
Doreen PippenVP MarketingProfile
William IIIChief OfficerProfile

About Maravai Lifesciences Management Performance

The success or failure of an entity such as Maravai Lifesciences often depends on how effective the management is. Maravai Lifesciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Maravai management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Maravai management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.22)(0.21)
Return On Capital Employed(0.25)(0.24)
Return On Assets(0.14)(0.14)
Return On Equity(0.45)(0.42)

Maravai Lifesciences Workforce Analysis

Traditionally, organizations such as Maravai Lifesciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Maravai Lifesciences within its industry.

Maravai Lifesciences Manpower Efficiency

Return on Maravai Lifesciences Manpower

Revenue Per Employee454.7K
Revenue Per Executive15.2M
Net Loss Per Employee455.5K
Net Loss Per Executive15.3M
Working Capital Per Employee652.9K
Working Capital Per Executive21.9M

Complementary Tools for Maravai Stock analysis

When running Maravai Lifesciences' price analysis, check to measure Maravai Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maravai Lifesciences is operating at the current time. Most of Maravai Lifesciences' value examination focuses on studying past and present price action to predict the probability of Maravai Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maravai Lifesciences' price. Additionally, you may evaluate how the addition of Maravai Lifesciences to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance